Compare Costco Wholesale Corporation (COST) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Sanofi SA — how do they compare? Costco Wholesale Corporation trades at $944.56 (market cap $420.05B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Costco Wholesale Corporation is far larger — about 4.4× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 132 Days and Sanofi SA for 94 Days on average.
| COST | SNY | |
|---|---|---|
Market Cap | $420.05B | $95.18B |
Volume | 2,087,565 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $52.34 |
52-Week Low | $849.63 | $39.51 |
Typical Hold Time | 132 Days | 94 Days |
Enterprise Value | $407.33B | $114.48B |
Dividend Yield | 0.62% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $942.25, up 0.7% on the day, showing strong operational momentum with a 28.4% ROE and 11.3% March sales growth. The stock is near its 52-week high, supported by bullish moving averages, though RSI levels indicate potential overbought conditions. Recent membership fee hikes and robust cash flow generation underscore its resilient business model.
Outlook remains positive given analyst consensus and a $1,090 price target, but elevated P/E of 45.66 poses valuation risk. Key catalysts include sustained membership growth and expansion, while risks involve competitive pressures and macroeconomic sensitivity.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
